Matrix metalloproteinases-7, -8, -9 and TIMP-1 in the follow-up of diisocyanate-induced asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 1, 2010, Pages 61-68

  Piirila P ^a   Lauhio, A ^a   Majuri, M L ^b   Meuronen, A ^c   Myllarniemi M ^a   Tervahartiala, T ^a   Vuorinen, K ^a   Laitinen, A ^c   Alenius, H ^b   Kinnula, V L ^a   Sorsa, T ^a,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diisocyanate induced asthma; Inflammation; Inhaled steroids; Matrix metalloproteinase 9

Indexed keywords

BUDESONIDE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GELATINASE B; HISTAMINE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; ISOCYANATE; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; ANTIASTHMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE;

ADULT; ARTICLE; ASTHMA; BRONCHOSCOPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE TEST; INFLAMMATION; LONGITUDINAL STUDY; LUNG LAVAGE; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROVOCATION TEST; SPIROMETRY; STEROID THERAPY; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE; ZYMOGRAPHY; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; IMMUNOLOGY; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; MALE; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TH2 CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 72049096643     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02146.x     Document Type: Article

References (35)

1. Elkington PTG, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005;142:12-20. (Pubitemid 41361000)
2. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006;173: 188-198. (Pubitemid 43187891)
3. Mattos W, Lim S, Russel R, Jatakanon A, Ching F, Barnes PJ. Matrix metalloproteinase-9 expression in asthma. Effect of asthma severity, allergen challenge and inhaled corticosteroids. Chest 2002;122:1543-1552.
4. Ohno I, Ohtani H, Nitta Y, Suzuki J, Hoski H, Honma M et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997;16:212-219. (Pubitemid 127497442)
5. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased release of matrix metalloproteinase- 9 bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 1997;17:583-591. (Pubitemid 127499061)
6. Lee KS, Jin SM, Lee H, Lee YC. Imbalance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in toluene diisocyanate-induced asthma. Clin Exp Allergy 2004;34:276-284. (Pubitemid 38315265)
7. Vignola AM, Riccobono L, Miragella A, Profita M, Chanez P, Bellia V et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945-1950. (Pubitemid 29008837)
8. Hoshino M, Takahashi M, Takai Ym Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999;104:356-363. (Pubitemid 29420433)
9. Chan-Yeung M. Occupational asthma. Chest 1990;98(5 Suppl.):148S-161S.
10. Saetta M, Di Stefano A, Maestrelli P, De Marzo N, Milani GF, Pivirotto F et al. Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am Rev Respir Dis 1992;145:160-168.
11. Saetta M, Maestrelli P, Di Stefano A, De Marzo N, Milani GF, Pivirotto F et al. Effect of cessation of exposure to toluene diisocyanate (TDI) on bronchial mucosa of subjects with TDI.induced asthma. Am Rev Respir Dis 1992;145:169-174.
12. Rachiotis G, Savani R, Brant A, MacNeill SJ, Newman Taylor A, Cullinan P. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax 2007;62:147-152. (Pubitemid 46271721)
13. Maestrelli P, de Marzo N, Saetta M, Boscaro M, Fabbri L, Mapp C. Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Am Rev Respir Dis 1993;148:407-412.
14. Piirilä P, Meuronen A, Majuri ML, Luukkonen R, Mäntylä T, Wolff H et al. Inflammation and functional outcome in diisocyanate-induced asthma after cessation of exposure. Allergy 2008;63:583-591.
15. Park H-S, Kim H-A, Jung J-W, Kim Y-K, Lee S-K, Kim S-S et al. Metalloproteinase-9 is increased after toluene diisocyanate exposure in the induced sputum from patients with toluene diisocyanate-induced asthma. Clin Exp Allergy 2003;33:113-118.
16. Piirilä P, Nordman H, Keskinen H, Luukkonen R, Salo SP, Tuomi T et al. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate- and toluene diisocyanate-induced asthma. Am J Respir Crit Care Med 2000;162:516-522. (Pubitemid 30647193)
17. Sovijä rvi ARA, Malmberg LP, Reinikainen K, Rytilä P, Poppius H. A rapid dosimetric method with controlled tidal breathing for histamine challenge: repeatability and distribution of bronchial reactivity in a clinical material. Chest 1993;104: 164-170.
18. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factoralpha and doxycycline. J Biol Chem 1997;272:3104-3109.
19. Tuomainen AM, Nyyssö nen K, Laukkanen JA, Tervahartiala T, Tuomainen T-P, Salonen JT et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722-2728.
20. Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 2001;84:1363-1371. (Pubitemid 32522105)
21. Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-21074. (Pubitemid 27373964)
22. Kjeldsen L, Bjerrum OW, Askaa J, Borregaard N. Subcellular localization and release of human neutrophil gelatinase, confirming the existence of separate gelatinase-containing granules. Biochem J 1992;287: 603-610.
23. Bosse M, Chakir J, Rouabhia M, Boulet L-P, Audette M, Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999;159:596-602. (Pubitemid 29084886)
24. Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 2005;78:279-288. (Pubitemid 40979967)
25. Imaizumi T, Hatakeyama M, Taima K, Ishikawa A, Yamashita K, Yoshida H et al. Effect of double-stranded RNA on the expression of epithelial neutrophil activating peptide-78/CXCL-5 in human endothelial cells. Inflammation 2004;28:215-219. (Pubitemid 41449421)
26. Magalhaes ES, Mourao-Sa DS, Vieira-de-Abreu A, Figueiredo RT, Pires AL, Farias- Filho FA et al. Macrophage migration inhibitory factor is essential for allergic asthma but not for Th2 differentiation. Eur J Immunol 2007;37:1097-1106.
27. Kong Y, Yu X, Tang J, Ouyang X, Huang X, Fingerle-Rowson G et al. Macrophage migration inhibitory factor induces MMP-9 expression: Implications for destabilization of human atherosclerotic plaques. Atherosclerosis 2005;178:207-215. (Pubitemid 39600835)
28. McMillan SJ, Kearley J, Campbell JD, Zhu X-W, Larbi KY, Shipley JM et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J Immunol 2004;172:2586-2594. (Pubitemid 38182410)
29. Yoon H-K, Cho H-Y, Kleeberger SR. Protective role of matrix metalloproteinase-9 in ozone-induced airway inflammation. Environ Health Perspect 2007;115:1557-1563.
30. Lee YC, Song C, Bum H, O J-L, Rhee YK, Park HS et al. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol 2001;108:1021-1026. (Pubitemid 33151557)
31. Lee KS, Jin SM, Kim SS, Lee YC. Doxycycline reduces airway inflammation and hyperresponsiveness in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2004;113:902-909. (Pubitemid 38608600)
32. Delclaux C, Delacourt C, d'Ortho M-P, Boyer V, Lfuma C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996;14:288-295.
33. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006;38: 306-321. (Pubitemid 44385100)
34. Cataldo DD, Gueders M, Munaut C, Rocsk N, Barthsch P, Foidart J-M et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics. Lab Invest 2004;84:418-424. (Pubitemid 41656469)
35. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004;172: 7791-7803. (Pubitemid 38747647)